Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Measles is highly contagious among those who are unvaccinated and may have severe health consequences in children under age 5 years.

The FDA has approved Emrelis for the treatment of adult patients with locally advanced or metastatic NSCLC with high c-Met protein overexpression.